Life Technologies Corporation

Life Technologies Corporation has been granted 1,296 US utility patents between 2015 and 2025, placing Life Technologies Corporation at rank #334 across all assignees tracked by PlainPatent. This portfolio spans 116 distinct Cooperative Patent Classification (CPC) subclasses, averaging 14.2 claims per patent with primary concentration in C12Q (MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS ; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICR). As a US Corporation, Life Technologies Corporation is one of the broader-portfolio assignees in the PatentsView dataset. The composite Innovation Score of 63.1/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.

Filing cadence tells the strategic story. Between 2020 and 2025 the company received 622 grants, compared with 674 in the 2015–2019 window — a -8% shift in five-year velocity. A cooling filing rate may reflect portfolio consolidation, shifting priorities, or reduced R&D throughput. The US Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.

Claim depth and technology breadth together indicate competitive posture. Life Technologies Corporation's 14.2 average claims per patent sits within the typical range for solid legal coverage without excessive prosecution cost, while a diversified footprint across 100+ CPC subclasses spreads risk across many technology fronts. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark Life Technologies Corporation against peers pursuing similar technology classes.